Nuveen Asset Management, LLC Editas Medicine, Inc. Transaction History

Nuveen Asset Management, LLC

$340 Billion
Q4 2024

A detailed history of Nuveen Asset Management, LLC transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 316,614 shares of EDIT stock, worth $1.13 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

316,614

Previous 256,031 23.66%

Holding current value

$1.13 Million

Previous $873,000 53.95%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$1.2 - $3.76 $72,699 - $227,792	60,583 Added 23.66%	316,614 $402,000
Q2 2024 Aug 09, 2024	SELL	$4.67 - $7.28 $3.58 Million - $5.58 Million	-767,149 Reduced 74.98%	256,031 $1.2 Million
Q1 2024 May 13, 2024	BUY	$7.03 - $11.07 $2.65 Million - $4.18 Million	377,377 Added 58.44%	1,023,180 $7.59 Million
Q4 2023 Feb 14, 2024	SELL	$6.25 - $11.11 $1.9 Million - $3.37 Million	-303,312 Reduced 31.96%	645,803 $6.54 Million
Q3 2023 Nov 14, 2023	BUY	$6.92 - $9.31 $1.82 Million - $2.45 Million	263,458 Added 38.42%	949,115 $7.4 Million
Q2 2023 Aug 14, 2023	BUY	$6.36 - $11.47 $1.29 Million - $2.32 Million	202,691 Added 41.97%	685,657 $5.64 Million
Q1 2023 May 15, 2023	SELL	$7.03 - $11.53 $1.46 Million - $2.39 Million	-207,325 Reduced 30.03%	482,966 $3.5 Million
Q4 2022 Feb 14, 2023	BUY	$8.32 - $13.21 $886,446 - $1.41 Million	106,544 Added 18.25%	690,291 $6.12 Million
Q3 2022 Nov 14, 2022	SELL	$12.16 - $19.42 $26,180 - $41,811	-2,153 Reduced 0.37%	583,747 $7.15 Million
Q2 2022 Aug 15, 2022	SELL	$9.99 - $21.35 $90,559 - $193,537	-9,065 Reduced 1.52%	585,900 $6.93 Million
Q1 2022 May 16, 2022	BUY	$14.08 - $27.63 $514,229 - $1.01 Million	36,522 Added 6.54%	594,965 $10.4 Million
Q4 2021 Feb 14, 2022	SELL	$26.55 - $40.57 $1.76 Million - $2.69 Million	-66,198 Reduced 10.6%	558,443 $16 Million
Q3 2021 Nov 12, 2021	BUY	$39.27 - $72.94 $948,331 - $1.76 Million	24,149 Added 4.02%	624,641 $39.5 Million
Q2 2021 Aug 16, 2021	BUY	$31.29 - $56.64 $3.57 Million - $6.47 Million	114,155 Added 23.47%	600,492 $34 Million
Q1 2021 May 17, 2021	BUY	$39.71 - $90.58 $599,779 - $1.37 Million	15,104 Added 3.21%	486,337 $20.4 Million
Q4 2020 Feb 16, 2021	BUY	$27.07 - $84.35 $49,619 - $154,613	1,833 Added 0.39%	471,233 $33 Million
Q3 2020 Nov 16, 2020	BUY	$28.06 - $37.16 $4.85 Million - $6.43 Million	172,940 Added 58.34%	469,400 $13.2 Million
Q2 2020 Aug 14, 2020	SELL	$18.5 - $34.34 $597,402 - $1.11 Million	-32,292 Reduced 9.82%	296,460 $8.77 Million
Q1 2020 May 14, 2020	BUY	$14.88 - $32.78 $1.1 Million - $2.42 Million	73,787 Added 28.94%	328,752 $6.52 Million
Q4 2019 Feb 14, 2020	BUY	$19.49 - $32.63 $899,872 - $1.51 Million	46,171 Added 22.11%	254,965 $7.55 Million
Q3 2019 Nov 14, 2019	BUY	$22.49 - $26.81 $564,431 - $672,850	25,097 Added 13.66%	208,794 $4.75 Million
Q2 2019 Aug 15, 2019	BUY	$20.48 - $27.76 $3.76 Million - $5.1 Million	183,697 New	183,697 $4.55 Million

Others Institutions Holding EDIT

# of Institutions

217

Shares Held

45.5M

Call Options Held

476K

Put Options Held

338K

View Full List

About Editas Medicine, Inc.

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $245M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

More about EDIT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.

Account

Nuveen Asset Management, LLC Editas Medicine, Inc. Transaction History